Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
Hypertension
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Renal autoregulation, Glomerular filtration rate, Type 1 diabetes
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes Age between 18 and 70 years Blood pressure ≥ 135 mm Hg systolic and/or ≥ 85 mm Hg diastolic or ongoing antihypertensive treatment Informed consent Exclusion Criteria: Diabetic nephropathy Other known kidney or renal tract disease Malignant hypertension Blood pressure > 170/105 at baseline or during AHT wash-out period Plasma potassium > 4.7 mmol/l Elevated plasma creatinine (>88 µmol/l for women and >100 µmol/l for men) Symptoms of Ischemic heart disease within 3 months prior to study start Previous cerebrovascular event (apoplexy, TCI) Abuse of medicine or alcohol Pregnancy or breastfeeding Woman of child-bearing age who are not using adequate contraception ASA treatment > 1g/day or regular use of NSAIDs Known allergy to or side-effects of spironolactone Inability to understand patient information